Drug Trial Radar · NCT07754045
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
202
Planned (sponsor's estimate)
Start
Feb 15, 2027
Primary completion
Feb 15, 2028
Study completion Feb 15, 2028
Sponsor
- Lead sponsor
- Lumos PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m\^2, between the ages of 60 and 85 years that have mild functional impairment.
Conditions
- Obesity & Overweight
Interventions
LUM-201Drug
Daily (AM) oral Tablet at 25 mg
PlaceboDrug
Daily (AM) oral Tablet
SemagludtideDrug
Daily (AM) oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26.Time frame: From Day 1 to week 26
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.